Medicaments comprising gene recombinant antibody against ganglioside gd3
AssigneeKyowa Hakko Kogyo Co., Ltd.
InventorsKenya SHITARA, Rinpei Niwa, Junji Kanazawa, Masao Asada
Life of this patent
Estimating the term…
Loading patent…
AssigneeKyowa Hakko Kogyo Co., Ltd.
InventorsKenya SHITARA, Rinpei Niwa, Junji Kanazawa, Masao Asada
Estimating the term…
In order to obtain high therapeutic effects in treating malignant tumors, particularly melanoma, a new therapeutic method having less side effects, or a new therapeutic method which can provide further high therapeutic effects at conventional doses of agents has been desired. An object of the present invention is to provide a medicament which can provide higher therapeutic effects than any one of a gene recombinant antibody against ganglioside GD3 or the antibody fragment thereof alone, and a substance which activates an immunocomponent cell and a substance having an antitumor activity alone, by combining a gene recombinant antibody against ganglioside GD3 or the antibody fragment thereof with at least one of a substance which activates an immunocomponent cell and a substance having an antitumor activity. Also, the medicament is expected to relieve side effects which were problems in the case of administration of individual single agents.
A method for treating a tumor, which comprises administering to a human in need thereof an effective amount of a human chimeric antibody against ganglioside GD3 or an antibody fragment of the human chimeric antibody in combination with an effective amount of IFNα,
Dependencies are inferred from the claim text.